Immunome (NASDAQ:IMNM) Reaches New 52-Week High After Analyst Upgrade

Immunome, Inc. (NASDAQ:IMNM)’s share price reached a new 52-week high during trading on Thursday after Truist Financial raised their price target on the stock from $37.00 to $38.00. Truist Financial currently has a buy rating on the stock. Immunome traded as high as $28.04 and last traded at $27.99, with a volume of 1561300 shares. The stock had previously closed at $26.25.

IMNM has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Barclays initiated coverage on Immunome in a research note on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target for the company. Wedbush upped their price objective on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Finally, Citigroup reissued a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Immunome presently has a consensus rating of “Moderate Buy” and an average target price of $34.64.

Insider Activity at Immunome

In related news, insider Kinney Horn sold 90,616 shares of the business’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the sale, the insider owned 50,366 shares in the company, valued at $1,263,682.94. The trade was a 64.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 11,048 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total value of $301,058.00. Following the completion of the transaction, the director directly owned 92,211 shares of the company’s stock, valued at approximately $2,512,749.75. The trade was a 10.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 682,310 shares of company stock valued at $15,675,566 in the last 90 days. 7.21% of the stock is owned by corporate insiders.

Trending Headlines about Immunome

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Investors remain focused on the FDA’s acceptance of Immunome’s varegacestat NDA and an April 2027 PDUFA decision date. The company also expects initial 2026 data from its Phase 1 IM-1021 ROR1 antibody-drug conjugate program, providing potential catalysts for the stock. Immunome catalysts and Strong Buy analysis
• Positive Sentiment: HC Wainwright maintained a Buy rating and projects a potential transition to profitability over the longer term, forecasting positive EPS of $0.40 in fiscal 2029 and $1.08 in fiscal 2030. These estimates support the longer-term investment case despite current losses.
• Neutral Sentiment: Director Isaac Barchas sold shares under a pre-arranged Rule 10b5-1 plan, including 98,712 shares from August 10–12 for roughly $2.6 million. The planned nature of the transactions makes them a less definitive signal about management’s current outlook, although the sales may weigh on sentiment. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the consensus loss of $0.51. The earnings miss triggered a recent gap lower and highlights continued cash-burn and execution risks for the clinical-stage biotechnology company. Immunome shares gap down after earnings miss
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for the near and medium term: Q3 2026 to $(0.65) from $(0.51), Q4 to $(0.68) from $(0.53), fiscal 2026 to $(2.45) from $(1.99), and fiscal 2027 to $(2.11) from $(1.72). The cuts suggest slower progress toward profitability, even though the firm retained its Buy rating.

Institutional Investors Weigh In On Immunome

Several hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP acquired a new position in shares of Immunome during the second quarter worth $25,000. KBC Group NV bought a new stake in shares of Immunome in the first quarter worth $60,000. Strs Ohio acquired a new stake in Immunome in the fourth quarter valued at $64,000. Assetmark Inc. increased its holdings in Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after purchasing an additional 1,442 shares during the period. Finally, State of Wyoming bought a new position in Immunome during the 2nd quarter worth $109,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Stock Performance

The stock has a market capitalization of $3.09 billion, a price-to-earnings ratio of -10.75 and a beta of 2.08. The company has a fifty day simple moving average of $22.20 and a 200 day simple moving average of $22.24.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.14). As a group, equities analysts predict that Immunome, Inc. will post -2.3 earnings per share for the current fiscal year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.